NL8400333A - Moederkoornalkaloiden, hun bereiding en hun toepassing. - Google Patents
Moederkoornalkaloiden, hun bereiding en hun toepassing. Download PDFInfo
- Publication number
- NL8400333A NL8400333A NL8400333A NL8400333A NL8400333A NL 8400333 A NL8400333 A NL 8400333A NL 8400333 A NL8400333 A NL 8400333A NL 8400333 A NL8400333 A NL 8400333A NL 8400333 A NL8400333 A NL 8400333A
- Authority
- NL
- Netherlands
- Prior art keywords
- formula
- compound
- acid addition
- compounds
- chj
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 2
- -1 (8 C) -1-ethyl-6-methyl-ergolin-8-yl Chemical group 0.000 claims 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 229960003133 ergot alkaloid Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DIJNKKIYOHCAPO-UHFFFAOYSA-N 2-benzhydryloxy-n,n-diethylethanamine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(OCCN(CC)CC)C1=CC=CC=C1 DIJNKKIYOHCAPO-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH86383 | 1983-02-16 | ||
CH86283 | 1983-02-16 | ||
CH86383A CH652720A5 (en) | 1983-02-16 | 1983-02-16 | Ergoline derivatives, their preparation and use |
CH862/83A CH652719A5 (en) | 1983-02-16 | 1983-02-16 | Ergoline derivatives, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
NL8400333A true NL8400333A (nl) | 1984-09-17 |
Family
ID=25685928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL8400333A NL8400333A (nl) | 1983-02-16 | 1984-02-03 | Moederkoornalkaloiden, hun bereiding en hun toepassing. |
Country Status (22)
Country | Link |
---|---|
US (1) | US4791116A (xx) |
AT (1) | AT386410B (xx) |
AU (1) | AU572822B2 (xx) |
CA (1) | CA1208630A (xx) |
DE (1) | DE3404400A1 (xx) |
DK (1) | DK67284A (xx) |
ES (1) | ES8505252A1 (xx) |
FI (1) | FI80034C (xx) |
FR (1) | FR2540874B1 (xx) |
GB (1) | GB2135307B (xx) |
GR (1) | GR81770B (xx) |
HU (1) | HU196399B (xx) |
IE (1) | IE56871B1 (xx) |
IL (1) | IL70954A (xx) |
IT (1) | IT1199062B (xx) |
MY (1) | MY8700270A (xx) |
NL (1) | NL8400333A (xx) |
NZ (1) | NZ207145A (xx) |
PH (1) | PH24707A (xx) |
PL (1) | PL246230A1 (xx) |
PT (1) | PT78101B (xx) |
SE (1) | SE459970B (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3915950A1 (de) * | 1989-05-12 | 1990-11-15 | Schering Ag | 8(alpha)-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1573621A (en) * | 1976-01-02 | 1980-08-28 | Sandoz Ltd | Acylated 6-methyl-8a-amino-ergoline i compounds |
US4348392A (en) * | 1974-07-19 | 1982-09-07 | Sandoz Ltd. | 8α-Substituted ergoline-I derivatives |
DE2656344A1 (de) * | 1975-12-23 | 1977-07-07 | Sandoz Ag | Ergolinderivate, ihre verwendung und herstellung |
CH622518A5 (en) * | 1976-12-14 | 1981-04-15 | Sandoz Ag | Process for the preparation of novel ergoline compounds |
WO1982000463A1 (en) * | 1980-07-25 | 1982-02-18 | Ag Sandoz | Ergoline derivatives,method for their preparation,pharmaceutical compositions containing them and their therapeutic application |
DE3151912A1 (de) * | 1981-12-23 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel |
PH21123A (en) * | 1983-04-28 | 1987-07-27 | Erba Farmitalia | Ergoline derivatives |
-
1984
- 1984-02-03 NL NL8400333A patent/NL8400333A/nl not_active Application Discontinuation
- 1984-02-03 HU HU84463A patent/HU196399B/hu not_active IP Right Cessation
- 1984-02-08 DE DE19843404400 patent/DE3404400A1/de not_active Withdrawn
- 1984-02-09 FR FR8402128A patent/FR2540874B1/fr not_active Expired
- 1984-02-13 PL PL24623084A patent/PL246230A1/xx unknown
- 1984-02-13 GB GB08403723A patent/GB2135307B/en not_active Expired
- 1984-02-14 CA CA000447409A patent/CA1208630A/en not_active Expired
- 1984-02-14 IT IT47681/84A patent/IT1199062B/it active
- 1984-02-14 GR GR73799A patent/GR81770B/el unknown
- 1984-02-14 PH PH30239A patent/PH24707A/en unknown
- 1984-02-14 DK DK67284A patent/DK67284A/da not_active Application Discontinuation
- 1984-02-14 NZ NZ207145A patent/NZ207145A/en unknown
- 1984-02-14 SE SE8400782A patent/SE459970B/sv not_active IP Right Cessation
- 1984-02-14 PT PT78101A patent/PT78101B/pt not_active IP Right Cessation
- 1984-02-14 FI FI840587A patent/FI80034C/fi not_active IP Right Cessation
- 1984-02-14 IL IL70954A patent/IL70954A/xx unknown
- 1984-02-15 AT AT0047984A patent/AT386410B/de not_active IP Right Cessation
- 1984-02-15 AU AU24625/84A patent/AU572822B2/en not_active Ceased
- 1984-02-15 IE IE353/84A patent/IE56871B1/xx unknown
- 1984-02-15 ES ES529759A patent/ES8505252A1/es not_active Expired
-
1986
- 1986-12-01 US US06/936,204 patent/US4791116A/en not_active Expired - Fee Related
-
1987
- 1987-12-30 MY MY270/87A patent/MY8700270A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK279109B6 (sk) | Imidazolové deriváty s bočným bifenylsulfonylmočov | |
IL49205A (en) | 5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole its production and pharmaceutical compositions containing it | |
KR870001105B1 (ko) | 신규 아미노과니딘 유도체의 제조방법 | |
EP0251453B1 (en) | Substituted amino-dihydrooxazoles, -thiazoles and -imidazoles, process for their preparation and pharmaceutical compositions containing them | |
CS239929B2 (en) | Processing of pyridazine derivatives | |
US4375472A (en) | Amidinosulphonic acid derivatives | |
KR950006891B1 (ko) | 아미노 알코올의 제조방법 | |
NL8400333A (nl) | Moederkoornalkaloiden, hun bereiding en hun toepassing. | |
EP0000355B1 (en) | New indole derivatives, processes for their preparation, and pharmaceutical compositions containing them. | |
EP0427526B1 (en) | Pyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | |
US4084001A (en) | Pharmacologically active compounds | |
US4152453A (en) | Pharmacologically active compounds and compositions and methods of use | |
JPH03167184A (ja) | N―ベンジルトロパンアミド類 | |
CZ66198A3 (cs) | Nové antikonvulzně účinné 1-ar(alk)yl-imidazolin-2-ony a způsob jejich přípravy | |
KR100491478B1 (ko) | 벤조[g]퀴놀린 유도체 | |
HU189562B (en) | Process for production of n-allil-5-chlor-n/4,5-dihydro-1/1-imidazol-2-il/-2,1-3-benzotiadiazol-4-amin | |
US4126670A (en) | Method of stimulating histamine H2 -receptors | |
CS231988B2 (en) | Manufacturing process of new ergoline derivatives | |
FR2572075A1 (fr) | Nouveaux derives de la 4-dioxino-(4,5-c)-pyridine et leur procede de preparation | |
CS208746B2 (en) | Method of making the 3,6-disubstituted-1,2,4-triazin 5-ons | |
KR900008563B1 (ko) | 에르고트 유도체의 제조방법 | |
FI68815C (fi) | Foerfarande foer framstaellning av terapeutiskt verkande 2-(2-klor-4-cyklopropylfenyl-imino)-imidazolidin | |
KR820000507B1 (ko) | N-[3-알킬아미노프로필]-n′-(치환된) 페닐요소의 제조방법 | |
HU190019B (hu) | Eljárás 8-(alkoxi'karbonil-amino)-4-áril-2-metil-tetrahidro -izokinolin-származékok előállítására | |
KR820000520B1 (ko) | N-<3-알킬아미노프로필>-n′-<(치환된)페닐>-요소의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A85 | Still pending on 85-01-01 | ||
BA | A request for search or an international-type search has been filed | ||
BB | A search report has been drawn up | ||
BV | The patent application has lapsed |